ロード中...
Anti-S1P antibody as a novel therapeutic strategy for VEGFR TKI resistant renal cancer
PURPOSE: VEGFR2 tyrosine kinase inhibition (TKI) is a valuable treatment approach for patients with metastatic RCC. However, resistance to treatment is inevitable. Identification of novel targets could lead to better treatment for both patients with TKI naïve or resistant RCC. EXPERIMENTAL DESIGN: I...
保存先:
| 出版年: | Clin Cancer Res |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4419371/ https://ncbi.nlm.nih.gov/pubmed/25589614 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2031 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|